<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Rev Inst Med Trop Sao Paulo</journal-id><journal-id journal-id-type="iso-abbrev">Rev. Inst. Med. Trop. Sao Paulo</journal-id><journal-id journal-id-type="publisher-id">rimtsp</journal-id><journal-title-group><journal-title>Revista do Instituto de Medicina Tropical de S&#x000e3;o Paulo</journal-title></journal-title-group><issn pub-type="ppub">0036-4665</issn><issn pub-type="epub">1678-9946</issn><publisher><publisher-name>Instituto de Medicina Tropical</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6648004</article-id><article-id pub-id-type="other">00402</article-id><article-id pub-id-type="doi">10.1590/S1678-9946201961035</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Kidney involvement in yellow fever: a review</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-1655-8095</contrib-id><name><surname>Lopes</surname><given-names>Renata Lima</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Pinto</surname><given-names>Jos&#x000e9; Reginaldo</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-8971-0994</contrib-id><name><surname>da Silva</surname><given-names>Geraldo Bezerra</given-names><suffix>Junior</suffix></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Santos</surname><given-names>Artur Keyler Teixeira</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Souza</surname><given-names>Maria Ta&#x000ed;s Oliveira</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Daher</surname><given-names>Elizabeth De Francesco</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>Canadian College of Microbiologists. Vancouver, British Columbia,
Canada</aff><aff id="aff2">
<label>2</label>Centro Universit&#x000e1;rio INTA, Curso de Enfermagem, Sobral, Cear&#x000e1;,
Brazil</aff><aff id="aff3">
<label>3</label>Universidade de Fortaleza, Curso de Medicina, Programas de
P&#x000f3;s-Gradua&#x000e7;&#x000e3;o em Sa&#x000fa;de Coletiva e Ci&#x000ea;ncias M&#x000e9;dicas, Fortaleza, Cear&#x000e1;, Brazil</aff><aff id="aff4">
<label>4</label>Universidade Federal do Cear&#x000e1;, Faculdade de Medicina, Departamento
de Medicina Cl&#x000ed;nica, Programa de P&#x000f3;s-Gradua&#x000e7;&#x000e3;o em Ci&#x000ea;ncias M&#x000e9;dicas, Fortaleza,
Cear&#x000e1;, Brazil</aff><author-notes><corresp id="c01"> Correspondence to: Geraldo Bezerra da Silva Junior Universidade
de Fortaleza, Curso de Medicina, Programas de P&#x000f3;s-Gradua&#x000e7;&#x000e3;o em Sa&#x000fa;de Coletiva e
Ci&#x000ea;ncias M&#x000e9;dicas, Av. Washington Soares, 1321, Bloco S, Sala S-01, CEP
60811-905, Fortaleza, CE, Brazil Tel: +55 85 34773280, +55 85 34773424 E-mail:
<email>geraldobezerrajr@unifor.br</email></corresp><fn fn-type="COI-statement"><p>CONFLICT OF INTERESTS</p><p>The authors declare no conflict of interests.</p></fn></author-notes><pub-date date-type="pub" publication-format="electronic"><day>22</day><month>7</month><year>2019</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2019</year></pub-date><volume>61</volume><elocation-id>e35</elocation-id><history><date date-type="received"><day>27</day><month>3</month><year>2019</year></date><date date-type="accepted"><day>24</day><month>6</month><year>2019</year></date></history><permissions><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"><license-p> This is an Open Access article distributed under the terms of the
Creative Commons Attribution Non-Commercial License, which permits
unrestricted non-commercial use, distribution, and reproduction in any
medium, provided the original work is properly cited. </license-p></license></permissions><abstract><title>ABSTRACT</title><p>Yellow fever is one of the most important mosquito-borne diseases, which still
affects a significant number of people every year, mainly in tropical countries.
Mortality can be high, even with intensive treatment due to multiple organ
failure, including acute kidney injury (AKI). This disease can also be a burden
on the health care system in developing countries, without mentioning the number
of lives that could be spared with an early diagnosis and adequate monitoring
and treatment. The pathophysiology of yellow fever-induced acute kidney injury
(AKI) is still to be completely understood, and the best clinical approach has
not yet been determined. This manuscript presents the most recent scientific
evidence of kidney involvement in yellow fever, since AKI plays an important
role in the mortality rate. Recent outbreaks have occurred in Brazil and further
studies are required to provide a better clinical control for patients with
yellow fever.</p></abstract><kwd-group><kwd>Yellow fever</kwd><kwd>Acute kidney injury</kwd><kwd>Epidemics</kwd><kwd>Pathophysiology</kwd></kwd-group><counts><fig-count count="3"/><table-count count="1"/><equation-count count="0"/><ref-count count="56"/></counts></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>The genus <italic>Flavivirus</italic> , of the <italic>Flaviviridade</italic> family,
is composed of some of the most pathogenic human viruses (Arboviruses), including
Dengue virus (DENV), Yellow fever virus (YFV), Zika virus (ZIKV) and West Nile virus
(WNV), among others<sup><xref rid="B1" ref-type="bibr">1</xref> - <xref rid="B4" ref-type="bibr">4</xref></sup> . These are mosquito-borne diseases transmitted by the same hematophagous
arthropod vectors, and their main hosts are vertebrate animals, with primates,
humans and non-humans, as hosts<sup><xref rid="B1" ref-type="bibr">1</xref> , <xref rid="B3" ref-type="bibr">3</xref> , <xref rid="B5" ref-type="bibr">5</xref></sup> .</p><p>Yellow fever virus, the etiological agent of YF, belongs to the
<italic>Flaviviridae</italic> family, genus <italic>Flavivirus,</italic> which
are enveloped positive-sense single-stranded RNA viruses<sup><xref rid="B6" ref-type="bibr">6</xref> - <xref rid="B8" ref-type="bibr">8</xref></sup> . The production of a single polyprotein of the YFV occurs after the virus
infects a host cell, thus beginning the translation of the viral genome. The thi
protein is cleaved by the YFV proteases of the host, producing viral proteins that
are essential for the virus genome replication and virion production<sup><xref rid="B7" ref-type="bibr">7</xref> , <xref rid="B9" ref-type="bibr">9</xref></sup> . A meticulous study of the yellow fever virus genome is essential to
establish genetic differences between virus strains, helping the development of new treatments<sup><xref rid="B7" ref-type="bibr">7</xref> , <xref rid="B9" ref-type="bibr">9</xref></sup> .</p><p>In Brazil, there have been no reports on an urban cycle of the mosquito since 1942.
However, the enzootic cycle (sylvatic yellow fever cycle involving non-human
primates) occurs in the Amazon basin region<sup><xref rid="B8" ref-type="bibr">8</xref> , <xref rid="B10" ref-type="bibr">10</xref></sup> .</p><p>In the last two years, there has been a recrudescence of yellow fever (YF) in some
countries in Africa and South America<sup><xref rid="B11" ref-type="bibr">11</xref></sup> , highlighting the need for effective tools and protocols against this
arboviral disease, enhancing medical practices and public health policies in this
field. As YF is not easily diagnosed, an adequate diagnosis constitutes the first
line of defense. Laboratory confirmation of suspected cases of YF must be promptly
performed, as it is imperative for the effective control of outbreaks and the
prevention of disease dissemination<sup><xref rid="B12" ref-type="bibr">12</xref></sup> .</p><p>The severe viscerotropic disease caused by YFV has a high mortality rate, ranging
from 25% to 50%<sup><xref rid="B13" ref-type="bibr">13</xref> - <xref rid="B15" ref-type="bibr">15</xref></sup> . The yellow fever virus is one of the most critical arboviruses. Annually,
this virus is globally responsible for many new cases of disease (approximately
200,000) and some of them are fatal (30,000 deaths)<sup><xref rid="B2" ref-type="bibr">2</xref> , <xref rid="B14" ref-type="bibr">14</xref> , <xref rid="B16" ref-type="bibr">16</xref> , <xref rid="B17" ref-type="bibr">17</xref></sup> .</p><p>Yellow fever causes a pan-systemic febrile illness, with hepatic, renal and
myocardial lesions. In more severe cases, internal hemorrhage, kidney failure,
shock, coma or even death can occur<sup><xref rid="B11" ref-type="bibr">11</xref></sup> . In the most severe cases, the mortality rate is between 20-50%<sup><xref rid="B15" ref-type="bibr">15</xref></sup> . Genetic factors seem to offer some protection, but according to Monath and Vasconcelos<sup><xref rid="B11" ref-type="bibr">11</xref></sup> , more studies are required to prove this hypothesis. Currently, specific
antiviral treatment is not available for yellow fever (YF). Prevention and
vaccination are the key control-factors in high-risk areas<sup><xref rid="B18" ref-type="bibr">18</xref></sup> . These areas are composed mainly of tropical forests in which the sylvatic
cycle was first described in the 1930s and early 1940s<sup><xref rid="B19" ref-type="bibr">19</xref> , <xref rid="B20" ref-type="bibr">20</xref></sup> .</p><p>A huge YF epidemic occurred in Rio de Janeiro/ Brazil between 1928 and 1929<sup><xref rid="B21" ref-type="bibr">21</xref></sup> . However, since 1942, no other cases have been reported in the major
Brazilian cities.</p><p>At the beginning of the 21<sup>th</sup> century, new cases of yellow fever outside
the rainforest environment have become a matter of concern for the Brazilian health
authorities due to the expansion of the viral circulation area and the possibility
of travelers carrying the virus to other countries<sup><xref rid="B21" ref-type="bibr">21</xref></sup> .</p><p>Some outbreaks and YF cases in non-epidemic areas have been reported. Since 2015,
Brazil has faced significant sylvatic yellow fever outbreaks in the four States of
the Southeast region, mainly due the insufficient vaccination coverage, since these
States are not YF epidemic areas<sup><xref rid="B22" ref-type="bibr">22</xref> , <xref rid="B23" ref-type="bibr">23</xref></sup> . In addition, by the end of the 20<sup>th</sup> century, the YF virus has
spread to the Atlantic forest regions (Southeast and South of Brazil) increasing the
number of infected primates and humans<sup><xref rid="B24" ref-type="bibr">24</xref></sup> .</p><p>YF urban outbreaks have been observed in Africa, as well. They occurred in December
2015, in Angola, and afterwards in the Democratic Republic of Congo in which
persisted until January 2017, according to The World Health Organization (WHO)<sup><xref rid="B25" ref-type="bibr">25</xref> - <xref rid="B27" ref-type="bibr">27</xref></sup> . This 2015 outbreak in Angola was considered the most significant and
widespread outbreak in Africa in more than 20 years<sup><xref rid="B20" ref-type="bibr">20</xref></sup> . Furthermore, in 2016, an unconnected yellow fever outbreak took place in
Uganda (Africa), and some occasional YF cases were reported in Chad, Ghana, Republic
of Congo and Guinea later on, and, more recently, Nigeria has been facing an active
yellow fever outbreak<sup><xref rid="B25" ref-type="bibr">25</xref> - <xref rid="B27" ref-type="bibr">27</xref></sup> .</p><sec><title>Historical aspects and epidemiology</title><p>There is convincing evidence to the hypothesis that sylvatic YFV was introduced
in the New World about four centuries ago, from West Africa to South America and
the Caribbean during the slave trafficking period<sup><xref rid="B17" ref-type="bibr">17</xref></sup> . It seems that the YFV could only have been introduced through people
presenting with viremia or by an infected vector ( <italic>A. aegypti</italic>
), as the yellow fever was very unusual on sailing ships<sup><xref rid="B3" ref-type="bibr">3</xref> , <xref rid="B28" ref-type="bibr">28</xref> , <xref rid="B29" ref-type="bibr">29</xref></sup> .</p><p>Since the 1950s, the transmission of YFV in the Americas occurred mainly through
a sylvatic cycle involving primates and mosquitoes ( <italic>Haemagogus</italic>
and <italic>Sabethes genera</italic> ). YFV is extremely pathogenic to primates
and non-immune people<sup><xref rid="B24" ref-type="bibr">24</xref> , <xref rid="B29" ref-type="bibr">29</xref></sup> . The epizootic cycle, which is responsible for sylvatic cycle epidemics,
appears in regular periods in some specific regions. Besides, the epizootic
cycle may overlap sporadic yellow fever outbreaks in non-immunized populations
that live in or close to the forest<sup><xref rid="B24" ref-type="bibr">24</xref></sup> .</p><p>Globally, Fernandes <italic>et al</italic> .<sup><xref rid="B30" ref-type="bibr">30</xref></sup> point out that the first probable exposure to YFV infection occurred 500
years ago, in 1585, in West Africa. Moreover, the first epidemic event was
recorded in the 17<sup>th</sup> century, when it was already considered a public
health threat. Moreover, the dissemination of the YFV in Brazil was associated
to trans-oceanic migrations, because these migrations brought the virus to
Brazil and it has gradually spread out to the Northeast and Midwest regions<sup><xref rid="B30" ref-type="bibr">30</xref></sup> .</p><p>Locations such as Africa and the Americas are considered areas of YFV epidemic
threat, due to their historical epidemic records even within the US<sup><xref rid="B31" ref-type="bibr">31</xref></sup> . Tretyakova <italic>et al</italic> .<sup><xref rid="B31" ref-type="bibr">31</xref></sup> mentioned that the World Health Organization (WHO) has estimated that
every year, 200,000 new cases of YF and 30,000 deaths will occur worldwide, even
though the YF current geographic distribution includes mainly African and South
American tropical areas.</p><p>Yellow fever sporadically disappears during the winter period<sup><xref rid="B18" ref-type="bibr">18</xref></sup> . According to the Brazilian Ministry of Health and the WHO<sup><xref rid="B32" ref-type="bibr">32</xref> , <xref rid="B33" ref-type="bibr">33</xref></sup> , yellow fever is a seasonal disease that mostly occurs during the
summer, with December and January being the hottest months in the Southern
Hemisphere, when there is a higher number of confirmed cases, as shown in <xref ref-type="fig" rid="f01">Figure 1</xref> .</p><p>
<fig id="f01" orientation="portrait" position="float"><label>Figure 1</label><caption><title>Distribution of confirmed cases of yellow fever in Brazil in the
seasonal monitoring period. Adapted from Minist&#x000e9;rio da
Sa&#x000fa;de32.</title></caption><graphic xlink:href="1678-9946-rimtsp-61-S1678-9946201961035-gf01"/></fig>
</p><p>Moreover, the Brazilian Ministry of Health published in February 2018 that 1,080
yellow fever cases were notified between July 2017 and January 2018, of which
213 were confirmed and 81 resulted in death<sup><xref rid="B32" ref-type="bibr">32</xref></sup> , as shown in <xref rid="t1" ref-type="table">Table 1</xref> .</p><p>
<table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Distribution of reported yellow fever cases in Brazil, from July
the 1st 2017 to January the 30th 2018.</title></caption><table frame="hsides" rules="groups"><colgroup width="14%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" style="font-weight:normal" rowspan="1" colspan="1">Region</th><th align="left" style="font-weight:normal" rowspan="1" colspan="1">Brazilian states
(probable site of infection)</th><th style="font-weight:normal" rowspan="1" colspan="1">Notified</th><th style="font-weight:normal" rowspan="1" colspan="1">Discarded</th><th style="font-weight:normal" rowspan="1" colspan="1">Under investigation</th><th style="font-weight:normal" rowspan="1" colspan="1">Confirmed</th><th style="font-weight:normal" rowspan="1" colspan="1">Death</th></tr></thead><tbody><tr><td rowspan="6" colspan="1">North</td><td rowspan="1" colspan="1">Amapa</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Amazonas</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Para</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Rondonia</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Roraima</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Tocantins</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td colspan="7" rowspan="1">
<hr/>
</td></tr><tr><td rowspan="6" colspan="1">Northeast</td><td rowspan="1" colspan="1">Bahia</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Ceara</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Maranhao</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Pernambuco</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Piaui</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Rio Grande do Norte</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td colspan="7" rowspan="1">
<hr/>
</td></tr><tr><td rowspan="4" colspan="1">Midwest</td><td rowspan="1" colspan="1">Distrito Federal</td><td align="center" rowspan="1" colspan="1">27</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">Goias</td><td align="center" rowspan="1" colspan="1">26</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Mato Grosso</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Mato Grosso do Sul</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td colspan="7" rowspan="1">
<hr/>
</td></tr><tr><td rowspan="4" colspan="1">Southeast</td><td rowspan="1" colspan="1">Espirito Santo</td><td align="center" rowspan="1" colspan="1">64</td><td align="center" rowspan="1" colspan="1">44</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Minas Gerais</td><td align="center" rowspan="1" colspan="1">244</td><td align="center" rowspan="1" colspan="1">71</td><td align="center" rowspan="1" colspan="1">96</td><td align="center" rowspan="1" colspan="1">77</td><td align="center" rowspan="1" colspan="1">30</td></tr><tr><td rowspan="1" colspan="1">Rio de Janeiro</td><td align="center" rowspan="1" colspan="1">34</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">27</td><td align="center" rowspan="1" colspan="1">7</td></tr><tr><td rowspan="1" colspan="1">Sao Paulo</td><td align="center" rowspan="1" colspan="1">573</td><td align="center" rowspan="1" colspan="1">216</td><td align="center" rowspan="1" colspan="1">249</td><td align="center" rowspan="1" colspan="1">108</td><td align="center" rowspan="1" colspan="1">43</td></tr><tr><td colspan="7" rowspan="1">
<hr/>
</td></tr><tr><td rowspan="3" colspan="1">South</td><td rowspan="1" colspan="1">Parana</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Rio Grande do Sul</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Santa Catarina</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td colspan="7" rowspan="1">
<hr/>
</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">Total</td><td align="center" rowspan="1" colspan="1">1,080</td><td align="center" rowspan="1" colspan="1">432</td><td align="center" rowspan="1" colspan="1">435</td><td align="center" rowspan="1" colspan="1">213</td><td align="center" rowspan="1" colspan="1">81</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>Adapted from Minist&#x000e9;rio da Sa&#x000fa;de<sup>32</sup>.</p></fn></table-wrap-foot></table-wrap>
</p><p>The Brazilian Amazon basin is an epidemic area for yellow fever. However,
sporadic outbreaks may occur outside this region, as shown in 2016, when
thousands of yellow fever cases in humans were reported (more than 1,900) in
Southeastern Brazil<sup><xref rid="B10" ref-type="bibr">10</xref></sup> .</p><p>According to the revised 2010 yellow fever map, Brazil is one of the 11 South
American countries within the YF endemic areas, and it is one of the seven
countries where vaccination is required<sup><xref rid="B19" ref-type="bibr">19</xref></sup> .</p><p>Fernandes <italic>et al</italic> .<sup><xref rid="B30" ref-type="bibr">30</xref></sup> briefly explained how these massive outbreaks spread to areas outside the
forest borders, by providing suitable environment for mosquitoes propagation in
large Brazilian cities. If the YFV is circulating in the forest, primates can be
infected, providing a new endemic area for sylvatic yellow fever. Therefore, the
YFV moves forward through the forest areas, reaching cities that had been
previously considered without risk of transmission<sup><xref rid="B30" ref-type="bibr">30</xref></sup> .</p><p>Because South America (particularly Brazil, Argentina, Paraguay, Bolivia, and
Peru) and African regions have notified YFV circulation<sup><xref rid="B34" ref-type="bibr">34</xref></sup> , and the displacement of asymptomatic patients infected with yellow
fever virus has implications for the global dissemination of yellow fever, it is
imperative that travelers are vaccinated, due the high risk of yellow fever transmission<sup><xref rid="B23" ref-type="bibr">23</xref> , <xref rid="B25" ref-type="bibr">25</xref> , <xref rid="B33" ref-type="bibr">33</xref></sup> .</p><p>Yellow fever was initially described only in Africa, and then the sailing ships
carrying slaves accidentally transported mosquitoes and infected people to the
South and Central Americas, where mosquitoes adapted to those regions due to
climate similarities and expanded their natural habitat. Currently, the areas
listed below, adapted from the WHO<sup><xref rid="B25" ref-type="bibr">25</xref> , <xref rid="B33" ref-type="bibr">33</xref> , <xref rid="B34" ref-type="bibr">34</xref></sup> reports, show the yellow fever geographic distribution worldwide ( <xref ref-type="fig" rid="f02">Figure 2</xref> ).</p><p>
<fig id="f02" orientation="portrait" position="float"><label>Figure 2</label><caption><title>Areas at risk of yellow fever transmission. Adapted from the
World Health Organization34.</title></caption><graphic xlink:href="1678-9946-rimtsp-61-S1678-9946201961035-gf02"/></fig>
</p></sec><sec><title>Pathogenesis and clinical manifestations</title><p>After the YFV-infected female mosquito bites, the virus infects dendritic cells
within subcutaneous tissues and travels to the lymph nodes, where the virus
replication occurs and the cellular immune response initiates. During this
feeding process, approximately 1,000 to 100,000 viruses are inoculated into the
host&#x02019;s bloodstream, starting the replication stage (since virus cannot replicate
outside a host). After this first RNA virus replication cycle, viruses are
released into the bloodstream through the lymphatic channels (viremia) and they
spread firstly to the regional lymph nodes. Then, they leave the lymph nodes and
reach different organs, especially the liver, heart and kidneys.</p><p>In humans, the wild-type YFV infection is mainly viscerotropic and affects
firstly the liver, before damaging other tissues, including the kidneys, spleen,
lymph nodes and heart. After the incubation period, the first infection phase
(1<sup>st</sup> stage) is characterized by a flu-like disease, during which
fever is accompanied by chills, headache, nausea and myalgia. Then, a period of
remission ensues, and most infected individuals recover. However, in the severe
forms of YF, after a brief remission period (2<sup>nd</sup> stage) of no more
than 48 h, some affected patients progress to the intoxication phase
(3<sup>rd</sup> stage)<sup><xref rid="B27" ref-type="bibr">27</xref> , <xref rid="B33" ref-type="bibr">33</xref> , <xref rid="B35" ref-type="bibr">35</xref></sup> .</p><p>In this third stage (intoxication phase), the hemorrhagic and hepatic
dysfunctions of this disease occur, and other multiple organ dysfunctions may
also come along. The intoxication stage is severe and accompanied by symptoms
characteristic of YF disease, including jaundice (which gave it the name of
&#x0201c;yellow fever&#x0201d;), vomiting (black vomit or dark vomit, other ancient names of the
disease) and other hemorrhagic manifestations such as vascular leakage<sup><xref rid="B8" ref-type="bibr">8</xref> , <xref rid="B27" ref-type="bibr">27</xref> , <xref rid="B36" ref-type="bibr">36</xref></sup> .</p><p>While the <italic>Haemagogus</italic> or <italic>Sabethes</italic> genera are the
wild vectors, the <italic>Aedes aegypti</italic> mosquito, easily found in
tropical cities, is the urban vector. <italic>A. aegypti</italic> is responsible
for the dissemination of yellow fever in the urban environment. Therefore, the
human-human transmission can occur when infected and non-infected humans are
confined together, in the presence of a competent bridge represented by a
domestic vector<sup><xref rid="B35" ref-type="bibr">35</xref></sup> .</p><p>The spectrum of clinical disease in humans is broad, and the severity of yellow
fever can cause symptoms ranging from inapparent infection to severe forms with
internal hemorrhage and acute hepatic and renal dysfunction. In humans, the YFV
mainly affects the liver, promoting hepatic dysfunction and subsequently
jaundice (yellowish skin). That was the reason the disease was named &#x0201c;yellow&#x0201d;
fever, but other organs such as the heart, lymph nodes, spleen, kidneys and
lungs are also viral replication sites<sup><xref rid="B35" ref-type="bibr">35</xref></sup> .</p><p>The initial symptoms are high fever, myalgia, low back pain, nausea and vomiting.
Moreover, the evolution to the severe form of disease presenting with jaundice,
hemorrhages, and, in some cases, multiple organ failure and shock may occur.
Opportunistic diseases may also appear, and, according to Maciel <italic>et
al</italic> .<sup><xref rid="B36" ref-type="bibr">36</xref></sup> , disseminated mycosis (severe infection in yellow fever patients) can
mimic bacterial sepsis.</p></sec><sec><title>Diagnosis and diagnostic methods</title><p>One of the greatest challenges in yellow fever is the diagnosis of disease,
because symptoms can be mistaken for other diseases such as respiratory,
digestive or urinary infections<sup><xref rid="B37" ref-type="bibr">37</xref></sup> . Therefore, due the lack of symptoms specificity in the early stages of
YF, the differential diagnosis is imperative, because yellow fever can be easily
mistaken for other hemorrhagic diseases, such as leptospirosis, dengue fever,
malaria and viral hepatitis<sup><xref rid="B2" ref-type="bibr">2</xref></sup> . Another important point is that YF shares the same vector and
geographic areas of other tropical diseases, such as zika, dengue and
chikungunya infections<sup><xref rid="B1" ref-type="bibr">1</xref> , <xref rid="B5" ref-type="bibr">5</xref></sup> .</p><p>Additionally, the quick identification of zika, dengue and chikungunya viruses
can indirectly help to control and prevent yellow fever, since the preventive
measures to control the vector of these diseases will be the same<sup><xref rid="B1" ref-type="bibr">1</xref></sup> . Therefore, technological advances especially the molecular biology
techniques, allow us to rapidly diagnose and differentiate diseases, and to be
more assertive. To exemplify, there is a multiplex real-time PCR assay (RT-PCR)
performed with primers and probes specifically designed to target and
differentiate ZIKV, DENV, CHIKV and YFV<sup><xref rid="B1" ref-type="bibr">1</xref> , <xref rid="B5" ref-type="bibr">5</xref></sup> . Another method that can be used is a single real-time RT-PCR assay, but
in this case RNA will be reverse transcribed and cDNA will be the target nucleic
acid of these viruses, and this technique can be very helpful to manage
outbreaks and control the spread of arboviral diseases<sup><xref rid="B1" ref-type="bibr">1</xref> , <xref rid="B2" ref-type="bibr">2</xref></sup> .</p><p>The YF laboratory diagnosis is attained through the detection of YF antigens by
measuring IgM (which is not always representative of a recent infection) and
IgG-specific antibody, when the patient has viremia<sup><xref rid="B3" ref-type="bibr">3</xref> , <xref rid="B4" ref-type="bibr">4</xref> , <xref rid="B14" ref-type="bibr">14</xref> , <xref rid="B33" ref-type="bibr">33</xref> , <xref rid="B38" ref-type="bibr">38</xref></sup> . To confirm the presence of YFV, it is necessary to use
immunohistochemical techniques to detect YF antigens in tissues or nucleic acids
detection using amplification methods, such as Mac-ELISA/IFA, PCR, RT-PCT or
other immunoassays such as flow cytometry, and microscopic analysis<sup><xref rid="B2" ref-type="bibr">2</xref> - <xref rid="B5" ref-type="bibr">5</xref> , <xref rid="B14" ref-type="bibr">14</xref> , <xref rid="B27" ref-type="bibr">27</xref> , <xref rid="B33" ref-type="bibr">33</xref> , <xref rid="B39" ref-type="bibr">39</xref> , <xref rid="B40" ref-type="bibr">40</xref></sup> . Laboratory investigation can also be performed by isolating the virus
or its antigens in blood and tissue samples, or through the
<italic>post-mortem</italic> histopathological analysis of tissues<sup><xref rid="B14" ref-type="bibr">14</xref> , <xref rid="B37" ref-type="bibr">37</xref></sup> , because the YF diagnosis is confirmed only through virus isolation
(gold standard)<sup><xref rid="B39" ref-type="bibr">39</xref></sup> . More recent molecular techniques, such as the Point of Care (POC), can
also be used to have more accurate laboratory diagnoses, using a portable equipment<sup><xref rid="B2" ref-type="bibr">2</xref></sup> . Nevertheless, it cannot be used in developing countries due to the lack
of investment in health care resources and laboratory equipment<sup><xref rid="B40" ref-type="bibr">40</xref></sup> . POC has been used to detect ZIKV, CHIKV and DENV due its portability,
specificity and sensitivity, using accessible samples such urine, saliva and
tiny amounts of blood<sup><xref rid="B41" ref-type="bibr">41</xref></sup> . POC can be a great monitoring and diagnostic tool for yellow fever as
well, because it can help to attain a faster diagnosis, being very specific,
with a relatively low cost.</p><p>According to Zarei<sup><xref rid="B40" ref-type="bibr">40</xref></sup> , POC portability could benefit resource-limited regions even though
there might be some barriers and challenges to overcome. However, the fact that
it can be used in the field and not only in clinical settings is another reason
that could help to attain a rapid diagnosis during outbreaks.</p><p>Other hemorrhagic diseases that constitute the differential diagnosis of yellow
fever have been studied in search of bioactive molecules and toll-like receptors
that can help to attain an accurate diagnosis<sup><xref rid="B41" ref-type="bibr">41</xref></sup> . This might indirectly help to diagnose YF when it is necessary to rule
out other hemorrhagic infections that mimic it.</p><p>Cytokines can also be elevated, such as interleukin 6 (IL-6), interferon
gamma-induced protein 10 (IP-10), monocyte chemoattractant protein 1 (MCP-1) and
tissue necrosis factor alpha (TNF-&#x003b1;)<sup><xref rid="B14" ref-type="bibr">14</xref></sup> , but because they are immune-mediated and appear in inflammatory
reactions, they are not specific for yellow fever.</p><p>Attaining a correct diagnosis is essential, especially if there are concomitant
infections, because yellow fever can quickly evolve to the severe forms of the
disease or even death<sup><xref rid="B4" ref-type="bibr">4</xref> , <xref rid="B41" ref-type="bibr">41</xref></sup> .</p></sec><sec><title>Kidney injury in yellow fever</title><p>One of the targets for viral replication are kidney tissues. Some histological
studies in non-human primates indicate that acute kidney tubular necrosis with
protein cylinders and hemoglobin cylinders has some similarities with some
classic histopathological findings of yellow fever in humans<sup><xref rid="B30" ref-type="bibr">30</xref></sup> . Maciel <italic>et al</italic> .<sup><xref rid="B36" ref-type="bibr">36</xref></sup> described in details the kidney lesions observed in the autopsy of
patients affected by the severe form of yellow fever virus infection, which was
associated to disseminated mycoses. In addition, according to the study by
Maciel <italic>et al</italic> .<sup><xref rid="B36" ref-type="bibr">36</xref></sup> , interstitial nephritis was identified, associated with tubular necrosis
and interlobular thrombosis in kidney vessels, as well as hemorrhage and
ischemic necrosis of the adrenal gland.</p><p>The autopsy of another yellow fever patient showed that there was preservation of
the parenchymal surface, showing only an irregular and hemorrhagic area in the
upper pole of the left kidney, and a 1.5-cm cyst on the anterior face of the
right kidney. The microscopic analysis revealed multiple interstitial nephritis
foci, combined with fibrosis and tubular necrosis. Thrombosis and intraluminal
inflammatory infiltrates were identified in the vessels. The suggestive
zygomycotic finding was characterized as a typical fungal hypha (pauci-septated
hyaline fungal hyphae with a lateral right-angle formation) in the intravascular
and interstitial inflammatory foci. Moreover, multiple foci of hemorrhagic
lesions and necrosis in the left adrenal gland were microscopically identified,
while the right adrenal gland was normal<sup><xref rid="B36" ref-type="bibr">36</xref></sup> .</p><p>Engelmann <italic>et al</italic> .<sup><xref rid="B42" ref-type="bibr">42</xref></sup> described granular bilirubin cylinders in the dilated distal convoluted
tubules and protein cylinders in the kidneys of animals that needed euthanasia.
Surprisingly, the yellow fever virus antigen was not detected in kidney tissues,
which indicates no association with the virus replication site.</p><p>As discussed by Engelmann <italic>et al</italic> .<sup><xref rid="B42" ref-type="bibr">42</xref></sup> , the yellow fever disease follows the same pattern in monkeys as
described in humans. However, it is more severe and develops faster in monkeys
than in humans. <italic>Rhesus</italic> primates were sacrificed after the
5<sup>th</sup> day of YFV infection and modifications in liver functions
were detected up to 24h before their death, whereas kidney abnormalities were
only detected in the late stages of the disease (18 to 12 h before death)
showing that these dysfunctions quickly led to death. Councilman bodies (areas
of hepatocyte degeneration) and Torres bodies (intranuclear eosinophilic
granular inclusions) have been demonstrated among <italic>post-mortem</italic>
findings. Moreover, all kidney sections evidenced tubular necrosis and protein
deposits that may lead to alterations in the kidney hemodynamics, renal azotemia
and eventually, renal failure<sup><xref rid="B14" ref-type="bibr">14</xref> , <xref rid="B21" ref-type="bibr">21</xref> , <xref rid="B42" ref-type="bibr">42</xref></sup> .</p><p>In general, kidney dysfunctions appear between the fifth and seventh day of the
disease, are characterized by the reduction of urinary volume and the urinary
loss of albumin (a common blood protein). One frequent finding is a urinary
volume lower than 500 mL/day, even if the patient is normovolemic, which may
evolve to anuria and acute tubular necrosis (ATN). At this stage, there is a
high rate of mortality. It is a fact that renal ischemia, intravascular
coagulation, shock and tubular toxicity are induced by bilirubin and by direct
effects of the virus on kidney tissues. If there is no improvement in kidney
function, renal replacement therapy is indicated (peritoneal dialysis or hemodialysis)<sup><xref rid="B43" ref-type="bibr">43</xref> , <xref rid="B44" ref-type="bibr">44</xref></sup> .</p><p>Although it is evident that there is damage in various organs such as the liver,
kidneys and lymphoid tissue, viral antigens are only detected in the liver.
According to Engelmann <italic>et al</italic> .<sup><xref rid="B42" ref-type="bibr">42</xref></sup> , these observations provide new information on the yellow fever
pathogenesis, suggesting that the kidney and the lymphoid tissue damage may not
be directly mediated by <italic>in situ</italic> viral replication, probably
occurring through soluble mediators that could be potentially produced elsewhere<sup><xref rid="B42" ref-type="bibr">42</xref></sup> .</p><p>The pathophysiology of yellow fever-associated acute kidney injury is illustrated
in <xref ref-type="fig" rid="f03">Figure 3</xref> .</p><p>
<fig id="f03" orientation="portrait" position="float"><label>Figure 3</label><caption><title>Pathophysiology of yellow fever-associated acute kidney injury.
Adapted from Daher and Silva Junior43.</title></caption><graphic xlink:href="1678-9946-rimtsp-61-S1678-9946201961035-gf03"/></fig>
</p><p>Unfortunately, there is no available biomarker to measure the glomerular
filtration rate and detect any kidney dysfunction accurately<sup><xref rid="B45" ref-type="bibr">45</xref></sup> .</p><p>Even though there are some widely used biomarkers to monitor the renal function
in chronic diseases such as the levels of urea, creatinine, cystatin C, inulin,
iothalamate and chromium-EDTA<sup><xref rid="B45" ref-type="bibr">45</xref> , <xref rid="B46" ref-type="bibr">46</xref></sup> , they are not helpful in yellow fever, because of the appalling disease
severity and progression. According to the WHO<sup><xref rid="B33" ref-type="bibr">33</xref></sup> , if there is hepato-renal failure, up to 50% of the patients will die
within 7 to 10 days, and those who do not die, may experience a long period of
recovery from liver and kidney damages<sup><xref rid="B15" ref-type="bibr">15</xref></sup> . Consequently, these data highlights the importance of more studies on
the kidney involvement in YF disease, because they are very important organs
that are indirect targets of the disease, with severe consequences.</p><p>About 20 to 50% of death cases involving liver and kidney failure due to YFV is a
significant high rate that should not be ignored. Additionally, renal supportive
and palliative care procedures have high costs, and can compromise the health of
patients living in developing countries since it will further burden the health
budget of these countries. That makes this disease even more frightening than it
could be, if the correct and early diagnosis, treatment and preventive measures
are not adequately applied and are overlooked.</p></sec><sec><title>Treatment</title><p>To date, yellow fever treatment consists of intensive support by providing
hydration, blood transfusions and, eventually, renal replacement therapy<sup><xref rid="B47" ref-type="bibr">47</xref></sup> . Some studies have shown that therapy remains limited to symptomatic
care in hospitals, and, in the most severe forms of the disease, patients must
be treated in intensive care units. Unfortunately, even though different
molecules (polyclonal anti-YFV, target viral factors and immunomodulatory
compounds) have shown some activity against the virus, both <italic>in
vitro</italic> and <italic>in vivo</italic> , they are not yet available for
clinical use and have not been approved, as well<sup><xref rid="B14" ref-type="bibr">14</xref> , <xref rid="B35" ref-type="bibr">35</xref></sup> .</p><p>Currently, some new therapeutic options have been evaluated, including antiviral
medication such as sofosbuvir. This drug is a direct antiviral inhibitor of the
RNA-directed RNA polymerase (NS5B) enzyme of hepatitis C virus, which is
essential for viral replication. This molecule incorporates into the RNA of
hepatitis C virus and inhibits its replication. This drug is activated in
hepatocytes, its prodrug is triphosphorylated and predominantly excreted by the kidney<sup><xref rid="B47" ref-type="bibr">47</xref> , <xref rid="B48" ref-type="bibr">48</xref></sup> .</p><p>Some mosquito-borne tropical diseases are deemed important and have been studied,
aiming to apply nanotechnology for the production of new drugs to treat diseases
such as dengue and malaria<sup><xref rid="B49" ref-type="bibr">49</xref></sup> . Nanotechnology aids in drug delivery, using biological organisms or
nanoparticles (that can be made of metals such as gold) making drugs more disease-specific<sup><xref rid="B49" ref-type="bibr">49</xref></sup> . There are no nanodrugs been studied for YF yet, since it is a neglected
disease, but there have been studies on nanopharmaceuticals for malaria, which
shares the same vector as YF<sup><xref rid="B49" ref-type="bibr">49</xref></sup> .</p></sec><sec><title>Prevention</title><p>Since YF is a mosquito-borne disease, its eradication can be quite challenging,
due to the presence of a sylvatic cycle of this disease, making it a serious
public health problem worldwide<sup><xref rid="B1" ref-type="bibr">1</xref> , <xref rid="B5" ref-type="bibr">5</xref> , <xref rid="B14" ref-type="bibr">14</xref></sup> . Having a mosquito as a vector makes YF hard to be eradicated,
justifying why it is essential to act on vector control measures<sup><xref rid="B14" ref-type="bibr">14</xref> , <xref rid="B37" ref-type="bibr">37</xref></sup> .</p><p>In 1927, the yellow fever virus strain Asibi isolated from a patient in Ghana was
used to formulate the first vaccine. The Asibi strain underwent serial passages
in chicken tissue cultures to be attenuated for human use as a vaccine, named
the 17D vaccine. There are two types of sub-strains obtained from the 17D
vaccine, the 17DD and 17D-204. The 17D strain was first used in Brazil in 1937
for vaccination purposes, and since then The Oswald Cruz Foundation has produced
the yellow fever 17DD (YF-17D) vaccine. To produce the 17DD vaccine, a sample of
the yellow fever virus is inoculated into pathogens-free embryonated chicken
eggs, as recommended by the WHO<sup><xref rid="B14" ref-type="bibr">14</xref> , <xref rid="B18" ref-type="bibr">18</xref></sup> .</p><p>Since its development in 1930, the YF-17D vaccine has been very effective as a
preventive action, inducing the production of neutralizing antibodies directed
against the viral envelope protein. Several vaccination strategies have been
implemented, including YF vaccination in children&#x02019;s routine vaccination
calendar, campaigns and providing vaccination coverage to travelers visiting
yellow fever risk zones. In addition to vaccination, vector control is
imperative and is also classified as a preventive action. Nevertheless, the
yellow fever virus can also be transmitted between humans by the Aedes mosquito,
the urban vector, resulting in urban epidemics. Therefore, yellow fever
surveillance that includes humans, animals (other primate hosts) and vectors
deserves special attention in Brazil, especially in the Southeast and Midwest regions<sup><xref rid="B14" ref-type="bibr">14</xref> , <xref rid="B19" ref-type="bibr">19</xref> , <xref rid="B20" ref-type="bibr">20</xref></sup> .</p><p>Between 2008 and 2009, the transmission of wild yellow fever occurred in Sao
Paulo and Rio Grande do Sul (Southeastern and Southern Brazilian States,
respectively). These cases of YF were characterized by their occurrence in a
wide geographic area in which population had no history of vaccination. In this
period, more than 22 million doses of the vaccine were distributed, and the
population was alerted to the possibility of vaccine-related adverse events. The
Brazilian health services detected and notified 112 severe cases, of which 56
had a causal association with the vaccine. Most of the confirmed adverse events
were associated with the vaccine: 47 cases (84%) had acute neurotropic disease
and all of them recovered; the other nine cases were classified as acute
viscerotropic disease and died<sup><xref rid="B50" ref-type="bibr">50</xref></sup> .</p><p>YF eradication constitutes a global challenge. The vaccine plays an important
role because it provides long-term humoral immunity<sup><xref rid="B50" ref-type="bibr">50</xref></sup> . Therefore, this long-term immunogenicity is very helpful and reduces
the morbidity and mortality of YF disease, since there is no specific treatment
for this disease to date<sup><xref rid="B50" ref-type="bibr">50</xref></sup> .</p><p>According to the WHO, a single dose of the vaccine is still very effective and
safe, providing long-lasting protection against YFV, and there are not many
reports on YF cases related to vaccination failure<sup><xref rid="B14" ref-type="bibr">14</xref> , <xref rid="B26" ref-type="bibr">26</xref> , <xref rid="B33" ref-type="bibr">33</xref> , <xref rid="B51" ref-type="bibr">51</xref> , <xref rid="B52" ref-type="bibr">52</xref></sup> . However, some adverse effects have been reported, although they were
all mild reactions that can also occur with other types of vaccines<sup><xref rid="B14" ref-type="bibr">14</xref> , <xref rid="B52" ref-type="bibr">52</xref></sup> .</p><p>Another very important action is to emphasize the importance of vaccinating
travelers going to endemic areas, such as Africa and South America countries and
encourage YF vaccination in these regions, where the mosquito and YF are endemic<sup><xref rid="B26" ref-type="bibr">26</xref> , <xref rid="B52" ref-type="bibr">52</xref></sup> .</p><p>According to Shearer <italic>et al</italic> .<sup><xref rid="B26" ref-type="bibr">26</xref></sup> , vaccination coverage has increased over the last 50 years due the
extensive vaccination campaigns, but it is still not enough to eliminate YFV<sup><xref rid="B53" ref-type="bibr">53</xref></sup> . Moreover, to help some countries in Africa that have faced recent YF
outbreaks, in June 2017 the WHO recommended the use of fractional doses of the
YF vaccine, if there is a chance of running out of the full vaccine dose<sup><xref rid="B54" ref-type="bibr">54</xref></sup> for the vaccination coverage of the population. However, the recommended
fractional dose should be above 1,000 UI, and it should be used only to avoid
the risk of YF spread, providing a one-year protection period<sup><xref rid="B53" ref-type="bibr">53</xref> , <xref rid="B54" ref-type="bibr">54</xref></sup> . It is only a palliative action in cases of low amounts of the vaccine
and during outbreaks<sup><xref rid="B53" ref-type="bibr">53</xref> , <xref rid="B54" ref-type="bibr">54</xref></sup> . For this reason, the WHO has been stimulating new discoveries using
viral genome sequencing to improve vaccines<sup><xref rid="B15" ref-type="bibr">15</xref></sup> , and some studies have shown that polyclonal antibody therapies are very
effective against many viruses<sup><xref rid="B55" ref-type="bibr">55</xref></sup> .</p></sec></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>As a viral disease with a huge impact, constituting a global public health concern,
YF remains poorly studied<sup><xref rid="B14" ref-type="bibr">14</xref> , <xref rid="B33" ref-type="bibr">33</xref> , <xref rid="B53" ref-type="bibr">53</xref></sup> . Some reports indicate that genetic variations of the disease may occur<sup><xref rid="B27" ref-type="bibr">27</xref></sup> . Other aspects that make yellow fever a challenging disease are its
similarity with other hemorrhagic fevers (other Flaviviruses, leptospirosis,
malaria), the sharing of the same endemics tropical areas, and the concomitance of
diseases such as the ones caused by other arboviruses<sup><xref rid="B3" ref-type="bibr">3</xref> , <xref rid="B41" ref-type="bibr">41</xref> , <xref rid="B56" ref-type="bibr">56</xref></sup> . These aspects can delay the diagnosis and management of patients including
adequate treatment and prevention measures.</p><p>Endemic areas would greatly benefit from more cost-effective and efficient YF assays
to control YF infection<sup><xref rid="B4" ref-type="bibr">4</xref></sup> . These could prevent outbreaks not only in endemic countries, but also in
other territories visited by travelers coming from endemic areas<sup><xref rid="B4" ref-type="bibr">4</xref></sup> . Unfortunately, serological diagnostic methods are not very accurate due the
low levels of circulating immunoglobulins and the high rate of cross-reactions
between arboviruses in serology. Thus, having access to a faster differential
diagnosis can help to implement the correct treatment and preventive measures<sup><xref rid="B3" ref-type="bibr">3</xref> , <xref rid="B4" ref-type="bibr">4</xref> , <xref rid="B27" ref-type="bibr">27</xref></sup> .</p><p>Even though yellow fever is a disease that has spread along the years throughout
tropical countries, it still requires more studies in some areas of medical
specialization for instance, in nephrology, as there is a scarcity of studies on the
kidney involvement in yellow fever. The kidney is a very complex organ and its
malfunction leads to YF severe forms, in some cases, requiring renal replacement therapy<sup><xref rid="B44" ref-type="bibr">44</xref></sup> .</p><p>The scarcity of studies on yellow fever-induced renal tissue damage can be associated
with the non-viral replication in kidney tissues<sup><xref rid="B42" ref-type="bibr">42</xref></sup> . Moreover, several cases have shown a variety of histological findings
related to kidney damage, such as interstitial nephritis, tubular necrosis,
interlobular thrombosis in kidney vessels, hemorrhage and adrenal gland ischemic necrosis<sup><xref rid="B21" ref-type="bibr">21</xref> , <xref rid="B30" ref-type="bibr">30</xref> , <xref rid="B36" ref-type="bibr">36</xref> , <xref rid="B42" ref-type="bibr">42</xref></sup> .</p><p>Although the yellow fever virus cannot be completely eradicated due to the existence
of a sylvatic cycle, it can be prevented if people from endemic areas and travelers
to risk areas are vaccinated and actions are taken to control the urban vector, the
Aedes mosquito<sup><xref rid="B19" ref-type="bibr">19</xref> , <xref rid="B20" ref-type="bibr">20</xref> , <xref rid="B53" ref-type="bibr">53</xref></sup> . These simple actions can at least prevent the spread of YF disease and new
outbreaks since the vaccination, to date, is the only available action against
yellow fever<sup><xref rid="B53" ref-type="bibr">53</xref> , <xref rid="B54" ref-type="bibr">54</xref></sup> . History shows that every time the vaccination was neglected in the past,
new cases of YF disease resurfaced<sup><xref rid="B27" ref-type="bibr">27</xref></sup> making it necessary to use fractional doses of the vaccine, which
unfortunately does not provide long-term protection<sup><xref rid="B53" ref-type="bibr">53</xref> , <xref rid="B54" ref-type="bibr">54</xref></sup> . Moreover, molecular biology studies using virus-like proteins (VLPs) could
be another source for vaccine production, which may show fewer side effects, since
VLPs do not contain viral genetic material<sup><xref rid="B56" ref-type="bibr">56</xref></sup> .</p><p>Therefore, the spread of yellow fever disease can be controlled. However, once the
disease is established, it is almost impossible to predict how severe it will be,
especially because its first symptoms can mimic a number of respiratory, digestive
and urinary non-severe infections<sup><xref rid="B4" ref-type="bibr">4</xref> , <xref rid="B33" ref-type="bibr">33</xref> , <xref rid="B36" ref-type="bibr">36</xref></sup> . So far, the treatment for this disease consists mainly of providing
intensive support<sup><xref rid="B33" ref-type="bibr">33</xref> , <xref rid="B47" ref-type="bibr">47</xref> , <xref rid="B53" ref-type="bibr">53</xref></sup> . The impact on important organs such as the liver and the kidneys can be fatal<sup><xref rid="B33" ref-type="bibr">33</xref></sup> and will constitute a burden to health care costs. For this reason, we
suggest that more studies on the kidney involvement in yellow fever and the early
diagnosis of kidney damage should be carried out to minimize the most feared
outcome, i.e., death, since the currently existing diagnostic tools neither help to
avoid the severe stages of the disease<sup><xref rid="B4" ref-type="bibr">4</xref></sup> , nor minimize the economic impact of YF sequelae.</p></sec></body><back><ref-list><title>REFERENCES</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mansuy</surname><given-names>JM</given-names></name><name><surname>Lhomme</surname><given-names>S</given-names></name><name><surname>Cazabat</surname><given-names>M</given-names></name><name><surname>Pasquier</surname><given-names>C</given-names></name><name><surname>Martin-Blondel</surname><given-names>G</given-names></name><name><surname>Izopet</surname><given-names>J</given-names></name></person-group><article-title>Detection of Zika, dengue and chikungunya viruses using
single-reaction multiplex real-time RT-PCR</article-title><source>Diagn Microbiol Infect Dis</source><year>2018</year><volume>92</volume><fpage>284</fpage><lpage>287</lpage><pub-id pub-id-type="pmid">30029808</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Domingo</surname><given-names>C</given-names></name><name><surname>Patel</surname><given-names>P</given-names></name><name><surname>Yillah</surname><given-names>J</given-names></name><name><surname>Weidmann</surname><given-names>M</given-names></name><name><surname>M&#x000e9;ndez</surname><given-names>JA</given-names></name><name><surname>Nakoun&#x000e9;</surname><given-names>ER</given-names></name><etal>et al</etal></person-group><article-title>Advanced yellow fever virus genome detection in point-of-care
facilities and reference laboratories</article-title><source>J Clin Microbiol</source><year>2012</year><volume>50</volume><fpage>4054</fpage><lpage>4060</lpage><pub-id pub-id-type="pmid">23052311</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higuera</surname><given-names>A</given-names></name><name><surname>Ram&#x000ed;rez</surname><given-names>JD</given-names></name></person-group><article-title>Molecular epidemiology of dengue, yellow fever, Zika and
Chikungunya arboviruses: an update</article-title><source>Acta Trop</source><year>2019</year><volume>190</volume><fpage>99</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">30444971</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stock</surname><given-names>NK</given-names></name><name><surname>Escadafal</surname><given-names>C</given-names></name><name><surname>Achazi</surname><given-names>K</given-names></name><name><surname>Ciss&#x000e9;</surname><given-names>M</given-names></name><name><surname>Niedrig</surname><given-names>M</given-names></name></person-group><article-title>Development and characterization of polyclonal peptide antibodies
for the detection of Yellow fever virus proteins</article-title><source>J Virol Methods</source><year>2015</year><volume>222</volume><fpage>110</fpage><lpage>116</lpage><pub-id pub-id-type="pmid">26086983</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>N</given-names></name><name><surname>Yan</surname><given-names>J</given-names></name><name><surname>Zhuo</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Development of multiplex real-time reverse-transcriptase
polymerase chain reaction assay for simultaneous detection of Zika, dengue,
yellow fever, and chikungunya viruses in a single tube</article-title><source>J Med Virol</source><year>2018</year><volume>90</volume><fpage>1681</fpage><lpage>1686</lpage><pub-id pub-id-type="pmid">29979812</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aubry</surname><given-names>F</given-names></name><name><surname>Nougair&#x000e8;de</surname><given-names>A</given-names></name><name><surname>Gould</surname><given-names>EA</given-names></name><name><surname>Lamballerie</surname><given-names>X</given-names></name></person-group><article-title>Flavivirus reverse genetic systems, construction techniques and
applications: a historical perspective</article-title><source>Antiviral Res</source><year>2015</year><volume>114</volume><fpage>67</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">25512228</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bozzacco</surname><given-names>L</given-names></name><name><surname>Yi</surname><given-names>Z</given-names></name><name><surname>Andreo</surname><given-names>U</given-names></name><name><surname>Conklin</surname><given-names>CR</given-names></name><name><surname>Li</surname><given-names>MM</given-names></name><name><surname>Rice</surname><given-names>CM</given-names></name><name><surname>MacDonald</surname><given-names>MR</given-names></name></person-group><article-title>Chaperone-assisted protein folding is critical for yellow fever
virus NS3/4A cleavage and replication</article-title><source>J Virol</source><year>2016</year><volume>90</volume><fpage>3212</fpage><lpage>3228</lpage><pub-id pub-id-type="pmid">26739057</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Klitting</surname><given-names>R</given-names></name><name><surname>Fischer</surname><given-names>C</given-names></name><name><surname>Drexler</surname><given-names>JF</given-names></name><name><surname>Gould</surname><given-names>EA</given-names></name><name><surname>Roiz</surname><given-names>D</given-names></name><name><surname>Paupy</surname><given-names>C</given-names></name><name><surname>Lamballerie</surname><given-names>X</given-names></name></person-group><article-title>What does the future hold for yellow fever virus?
(II)</article-title><source>Genes</source><publisher-loc>Basel</publisher-loc><year>2018</year><volume>9</volume><size units="pages">E425</size></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez-Garcia</surname><given-names>MD</given-names></name><name><surname>Meertens</surname><given-names>L</given-names></name><name><surname>Chazal</surname><given-names>M</given-names></name><name><surname>Hafirassou</surname><given-names>ML</given-names></name><name><surname>Dejarnac</surname><given-names>O</given-names></name><name><surname>Zamborlini</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Vaccine and wild-type strains of yellow fever virus engage
distinct entry mechanisms and differentially stimulate antiviral immune
responses</article-title><source>MBio</source><year>2016</year><volume>7</volume><elocation-id>e01956-15</elocation-id><pub-id pub-id-type="pmid">26861019</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rezende</surname><given-names>IM</given-names></name><name><surname>Sacchetto</surname><given-names>L</given-names></name><name><surname>Munhoz de Mello</surname><given-names>E</given-names></name><name><surname>Alves</surname><given-names>PA</given-names></name><name><surname>Iani</surname><given-names>FC</given-names></name><name><surname>Adelino</surname><given-names>TE</given-names></name><etal>et al</etal></person-group><article-title>Persistence of yellow fever virus outside the Amazon Basin,
causing epidemics in Southeast Brazil, from 2016 to 2018</article-title><source>PLoS Negl Trop Dis</source><year>2018</year><volume>12</volume><elocation-id>e0006538</elocation-id><pub-id pub-id-type="pmid">29864115</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monath</surname><given-names>TP</given-names></name><name><surname>Vasconcelos</surname><given-names>PF</given-names></name></person-group><article-title>Yellow fever</article-title><source>J Clin Virol</source><year>2015</year><volume>64</volume><fpage>160</fpage><lpage>173</lpage><pub-id pub-id-type="pmid">25453327</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Domingo</surname><given-names>C</given-names></name><name><surname>Charrel</surname><given-names>RN</given-names></name><name><surname>Schmidt-Chanasit</surname><given-names>J</given-names></name><name><surname>Zeller</surname><given-names>H</given-names></name><name><surname>Reusken</surname><given-names>C</given-names></name></person-group><article-title>Yellow fever in the diagnostics laboratory</article-title><source>Emerg Microbes Infect</source><year>2018</year><volume>7</volume><size units="pages">129</size></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbosa</surname><given-names>CM</given-names></name><name><surname>Di Paola</surname><given-names>N</given-names></name><name><surname>Cunha</surname><given-names>MP</given-names></name><name><surname>Rodrigues-Jesus</surname><given-names>MJ</given-names></name><name><surname>Ara&#x000fa;jo</surname><given-names>DB</given-names></name><name><surname>Silveira</surname><given-names>VB</given-names></name><etal>et al</etal></person-group><article-title>Yellow fever virus RNA in urine and semen of convalescent
patient, Brazil</article-title><source>Emerg Infect Dis</source><year>2018</year><volume>24</volume><fpage>176</fpage><lpage>178</lpage></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beasley</surname><given-names>DW</given-names></name><name><surname>McAuley</surname><given-names>AJ</given-names></name><name><surname>Bente</surname><given-names>DA</given-names></name></person-group><article-title>Yellow fever virus: genetic and phenotypic diversity and
implications for detection, prevention and therapy</article-title><source>Antiviral Res</source><year>2015</year><volume>115</volume><fpage>48</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">25545072</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pestana</surname><given-names>CP</given-names></name><name><surname>Lawson-Ferreira</surname><given-names>R</given-names></name><name><surname>Lessa-Aquino</surname><given-names>C</given-names></name><name><surname>Leal</surname><given-names>ML</given-names></name><name><surname>Freire</surname><given-names>MS</given-names></name><name><surname>Homma</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Sanger-based sequencing technology for yellow fever vaccine
genetic quality control</article-title><source>J Virol Methods</source><year>2018</year><volume>260</volume><fpage>82</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">30009851</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Douam</surname><given-names>F</given-names></name><name><surname>Soto Albrecht</surname><given-names>YE</given-names></name><name><surname>Hrebikova</surname><given-names>G</given-names></name><name><surname>Sadimin</surname><given-names>E</given-names></name><name><surname>Davidson</surname><given-names>C</given-names></name><name><surname>Kotenko</surname><given-names>SV</given-names></name><etal>et al</etal></person-group><article-title>Type III interferon-mediated signaling is critical for
controlling live attenuated yellow fever virus infection in
vivo</article-title><source>MBio</source><year>2017</year><volume>8</volume><elocation-id>e00819-17</elocation-id><pub-id pub-id-type="pmid">28811340</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saavedra</surname><given-names>M</given-names></name></person-group><article-title>Early-life disease exposure and occupational status: the impact
of yellow fever during the 19<sup>th</sup>century</article-title><source>Explor Econ Hist</source><year>2017</year><volume>64</volume><fpage>62</fpage><lpage>81</lpage></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manso</surname><given-names>PP</given-names></name><name><surname>Dias de Oliveira</surname><given-names>BC</given-names></name><name><surname>Carvalho de Sequeira</surname><given-names>P</given-names></name><name><surname>Rodrigues Maia de Souza</surname><given-names>Y</given-names></name><name><surname>Santos Ferro</surname><given-names>JM</given-names></name><name><surname>Silva</surname><given-names>IJ</given-names></name><etal>et al</etal></person-group><article-title>Kinetic study of yellow fever 17DD viral infection in Gallus
gallus domesticus embryos</article-title><source>PLoS One</source><year>2016</year><volume>11</volume><elocation-id>e0155041</elocation-id><pub-id pub-id-type="pmid">27158977</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romano</surname><given-names>AP</given-names></name><name><surname>Costa</surname><given-names>ZG</given-names></name><name><surname>Ramos</surname><given-names>DG</given-names></name><name><surname>Andrade</surname><given-names>MA</given-names></name><name><surname>Jayme</surname><given-names>VS</given-names></name><name><surname>Almeida</surname><given-names>MA</given-names></name><etal>et al</etal></person-group><article-title>Yellow fever outbreaks in unvaccinated populations, Brazil,
2008&#x02013;2009</article-title><source>PLoS Negl Trop Dis</source><year>2014</year><volume>8</volume><size units="pages">e2740</size></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shearer</surname><given-names>FM</given-names></name><name><surname>Longbottom</surname><given-names>J</given-names></name><name><surname>Browne</surname><given-names>AJ</given-names></name><name><surname>Pigott</surname><given-names>DM</given-names></name><name><surname>Brady</surname><given-names>OJ</given-names></name><name><surname>Kraemer</surname><given-names>MU</given-names></name><etal>et al</etal></person-group><article-title>Existing and potential infection risk zones of yellow fever
worldwide: a modelling analysis</article-title><source>Lancet Glob Health</source><year>2018</year><volume>6</volume><fpage>e270</fpage><lpage>e278</lpage><pub-id pub-id-type="pmid">29398634</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cavalcante</surname><given-names>KR</given-names></name><name><surname>Tauil</surname><given-names>PL</given-names></name></person-group><article-title>Risk of re-emergence of urban yellow fever in
Brazil</article-title><source>Epidemiol Serv Sa&#x000fa;de</source><year>2017</year><volume>26</volume><fpage>617</fpage><lpage>620</lpage><pub-id pub-id-type="pmid">28977185</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selemane</surname><given-names>I</given-names></name></person-group><article-title>Epidemiological monitoring of the last outbreak of yellow fever
in Brazil: an outlook from Portugal</article-title><source>Travel Med Infect Dis</source><year>2019</year><volume>28</volume><fpage>46</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">30583006</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Possas</surname><given-names>C</given-names></name><name><surname>Louren&#x000e7;o-de-Oliveira</surname><given-names>R</given-names></name><name><surname>Tauil</surname><given-names>PL</given-names></name><name><surname>Pinheiro</surname><given-names>FP</given-names></name><name><surname>Pissinatti</surname><given-names>A</given-names></name><name><surname>Cunha</surname><given-names>RV</given-names></name><etal>et al</etal></person-group><article-title>Yellow fever outbreak in Brazil: the puzzle of rapid viral spread
and challenges for immunisation</article-title><source>Mem Inst Oswaldo Cruz</source><year>2018</year><volume>113</volume><elocation-id>e180278</elocation-id><pub-id pub-id-type="pmid">30427974</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mir</surname><given-names>D</given-names></name><name><surname>Delatorre</surname><given-names>E</given-names></name><name><surname>Bonaldo</surname><given-names>M</given-names></name><name><surname>Louren&#x000e7;o-de-Oliveira</surname><given-names>R</given-names></name><name><surname>Vicente</surname><given-names>AC</given-names></name><name><surname>Bello</surname><given-names>G</given-names></name></person-group><article-title>Phylodynamics of yellow fever virus in the Americas: new insights
into the origin of the 2017 Brazilian outbreak</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><size units="pages">7385</size></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><source>Immunization, vaccines and biologicals: yellow fever</source><date-in-citation content-type="cited-date">cited 2019 Jun 24</date-in-citation><comment><ext-link ext-link-type="uri" xlink:href="https://www.who.int/immunization/diseases/yellow_fever/en/">https://www.who.int/immunization/diseases/yellow_fever/en/</ext-link></comment></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shearer</surname><given-names>FM</given-names></name><name><surname>Moyes</surname><given-names>CL</given-names></name><name><surname>Pigott</surname><given-names>DM</given-names></name><name><surname>Brady</surname><given-names>OJ</given-names></name><name><surname>Marinho</surname><given-names>F</given-names></name><name><surname>Deshpande</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Global yellow fever vaccination coverage from 1970 to 2016: an
adjusted retrospective analysis</article-title><source>Lancet Infect Dis</source><year>2017</year><volume>17</volume><fpage>1209</fpage><lpage>1217</lpage><pub-id pub-id-type="pmid">28822780</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ingelbeen</surname><given-names>B</given-names></name><name><surname>Weregemere</surname><given-names>NA</given-names></name><name><surname>Noel</surname><given-names>H</given-names></name><name><surname>Tshapenda</surname><given-names>GP</given-names></name><name><surname>Mossoko</surname><given-names>M</given-names></name><name><surname>Nsio</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Urban yellow fever outbreak-Democratic Republic of the Congo,
2016: towards more rapid case detection</article-title><source>PLoS Negl Trop Dis</source><year>2018</year><volume>12</volume><elocation-id>e0007029</elocation-id><pub-id pub-id-type="pmid">30532188</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanley</surname><given-names>KA</given-names></name><name><surname>Monath</surname><given-names>TP</given-names></name><name><surname>Weaver</surname><given-names>SC</given-names></name><name><surname>Rossi</surname><given-names>SL</given-names></name><name><surname>Richman</surname><given-names>RL</given-names></name><name><surname>Vasilakis</surname><given-names>N</given-names></name></person-group><article-title>Fever versus fever: the role of host and vector susceptibility
and interspecific competition in shaping the current and future
distributions of the sylvatic cycles of dengue virus and yellow fever
virus</article-title><source>Infect Genet Evol</source><year>2013</year><volume>19</volume><fpage>292</fpage><lpage>311</lpage><pub-id pub-id-type="pmid">23523817</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chippaux</surname><given-names>JP</given-names></name><name><surname>Chippaux</surname><given-names>A</given-names></name></person-group><article-title>Yellow fever in Africa and the Americas: a historical and
epidemiological perspective</article-title><source>J Venom Anim Toxins Incl Trop Dis</source><year>2018</year><volume>24</volume><size units="pages">20</size></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandes</surname><given-names>NC</given-names></name><name><surname>Cunha</surname><given-names>MS</given-names></name><name><surname>Guerra</surname><given-names>JM</given-names></name><name><surname>R&#x000e9;ssio</surname><given-names>RA</given-names></name><name><surname>Cirqueira</surname><given-names>CS</given-names></name><name><surname>Iglezias</surname><given-names>SD</given-names></name><etal>et al</etal></person-group><article-title>Outbreak of yellow fever among nonhuman primates, Espirito Santo,
Brazil, 2017</article-title><source>Emerg Infect Dis</source><year>2017</year><volume>23</volume><fpage>2038</fpage><lpage>2041</lpage><pub-id pub-id-type="pmid">29148378</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tretyakova</surname><given-names>I</given-names></name><name><surname>Nickols</surname><given-names>B</given-names></name><name><surname>Hidajat</surname><given-names>R</given-names></name><name><surname>Jokinen</surname><given-names>J</given-names></name><name><surname>Lukashevich</surname><given-names>IS</given-names></name><name><surname>Pushko</surname><given-names>P</given-names></name></person-group><article-title>Plasmid DNA initiates replication of yellow fever vaccine in
vitro and elicits virus-specific</article-title><source>Virology</source><year>2014</year><season>-</season><fpage>28</fpage><lpage>35</lpage></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Brasil</collab><collab>Minist&#x000e9;rio da Sa&#x000fa;de</collab></person-group><source>Minist&#x000e9;rio da Sa&#x000fa;de atualiza casos de febre amarela</source><publisher-loc>Bras&#x000ed;lia</publisher-loc><publisher-name>Minist&#x000e9;rio da Sa&#x000fa;de</publisher-name><year>2018</year><date-in-citation content-type="cited-date">cited 2019 Jun 24</date-in-citation><comment><ext-link ext-link-type="uri" xlink:href="http://portalms.saude.gov.br/noticias/agencia-saude/42422-ministerio-da-saude-atualiza-casos-de-febre-amarela-30-jan">http://portalms.saude.gov.br/noticias/agencia-saude/42422-ministerio-da-saude-atualiza-casos-de-febre-amarela-30-jan</ext-link></comment></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><article-title>Vaccines and vaccination against yellow fever. WHO Position Paper
&#x02013; June 2013</article-title><source>Wkly Epidemiol Rec</source><year>2013</year><volume>88</volume><fpage>269</fpage><lpage>283</lpage><pub-id pub-id-type="pmid">23909008</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><source>Emergencies preparedness, response: yellow fever: a current
threat</source><date-in-citation content-type="cited-date">cited 2019 Jun 24</date-in-citation><comment><ext-link ext-link-type="uri" xlink:href="https://www.who.int/csr/disease/yellowfev/impact1/en/">https://www.who.int/csr/disease/yellowfev/impact1/en/</ext-link></comment></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klitting</surname><given-names>R</given-names></name><name><surname>Roth</surname><given-names>L</given-names></name><name><surname>Rey</surname><given-names>FA</given-names></name><name><surname>Lamballerie</surname><given-names>X</given-names></name></person-group><article-title>Molecular determinants of yellow fever virus pathogenicity in
Syrian golden hamsters: one mutation away from virulence</article-title><source>Emerg Microb Infect</source><year>2018</year><volume>7</volume><size units="pages">51</size></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maciel</surname><given-names>GV</given-names></name><name><surname>Tavares</surname><given-names>MC</given-names></name><name><surname>Pereira</surname><given-names>LS</given-names></name><name><surname>Silva</surname><given-names>GL</given-names></name><name><surname>Oliveira</surname><given-names>NR</given-names></name><name><surname>Paulino</surname><given-names>E</given-names><suffix>J&#x000fa;nior</suffix></name><etal>et al</etal></person-group><article-title>Disseminated mycosis in a patient with yellow
fever</article-title><source>Autops Case Rep</source><year>2018</year><volume>8</volume><elocation-id>e2018038</elocation-id><pub-id pub-id-type="pmid">30123781</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Escadafal</surname><given-names>C</given-names></name><name><surname>Faye</surname><given-names>O</given-names></name><name><surname>Sall</surname><given-names>AA</given-names></name><name><surname>Faye</surname><given-names>O</given-names></name><name><surname>Weidmann</surname><given-names>M</given-names></name><name><surname>Strohmeier</surname><given-names>O</given-names></name><etal>et al</etal></person-group><article-title>Rapid molecular assays for the detection of yellow fever virus in
low-resource settings</article-title><source>PLoS Negl Trop Dis</source><year>2014</year><volume>8</volume><elocation-id>e2730</elocation-id><pub-id pub-id-type="pmid">24603874</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Ibrahim</surname><given-names>F</given-names></name><name><surname>Thio</surname><given-names>TH</given-names></name><name><surname>Faisal</surname><given-names>T</given-names></name><name><surname>Neuman</surname><given-names>M</given-names></name></person-group><article-title>The application of biomedical engineering techniques to the
diagnosis and management of tropical diseases: a review</article-title><source>Sensors</source><publisher-loc>Basel</publisher-loc><year>2015</year><volume>15</volume><fpage>6947</fpage><lpage>6995</lpage><pub-id pub-id-type="pmid">25806872</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribeiro</surname><given-names>M</given-names></name><name><surname>Antunes</surname><given-names>CM</given-names></name></person-group><article-title>Febre amarela: estudo de um surto</article-title><source>Rev Soc Bras Med Trop</source><year>2009</year><volume>42</volume><fpage>523</fpage><lpage>531</lpage><pub-id pub-id-type="pmid">19967234</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zarei</surname><given-names>M</given-names></name></person-group><article-title>Infectious pathogens meet point-of-care
diagnostics</article-title><source>Biosens Bioelectron</source><year>2018</year><volume>106</volume><fpage>193</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">29428589</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Priya</surname><given-names>SP</given-names></name><name><surname>Sakinah</surname><given-names>S</given-names></name><name><surname>Sharmilah</surname><given-names>K</given-names></name><name><surname>Hamat</surname><given-names>RA</given-names></name><name><surname>Sekawi</surname><given-names>Z</given-names></name><name><surname>Higuchi</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Leptospirosis: molecular trial path and immunopathogenesis
correlated with dengue, malaria and mimetic hemorrhagic
infections</article-title><source>Acta Trop</source><year>2017</year><volume>176</volume><fpage>206</fpage><lpage>223</lpage><pub-id pub-id-type="pmid">28823908</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engelmann</surname><given-names>F</given-names></name><name><surname>Josset</surname><given-names>L</given-names></name><name><surname>Girke</surname><given-names>T</given-names></name><name><surname>Park</surname><given-names>B</given-names></name><name><surname>Barron</surname><given-names>A</given-names></name><name><surname>Dewane</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Pathophysiologic and transcriptomic analyses of viscerotropic
yellow fever in a rhesus macaque model</article-title><source>PLoS Negl Trop Dis</source><year>2014</year><volume>8</volume><size units="pages">e3295</size></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Daher</surname><given-names>EF</given-names></name><name><surname>Silva</surname><given-names>GB</given-names><suffix>Junior</suffix></name></person-group><chapter-title>Nefropatia nas doen&#x000e7;as tropicais</chapter-title><person-group person-group-type="editor"><name><surname>Riella</surname><given-names>MC</given-names></name><role>editor</role></person-group><source>Princ&#x000ed;pios de nefrologia e dist&#x000fa;rbios hidreletrol&#x000ed;ticos</source><edition>6a</edition><publisher-loc>Rio de Janeiro</publisher-loc><publisher-name>Guanabara-Koogan</publisher-name><year>2018</year><fpage>553</fpage><lpage>581</lpage></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Daher</surname><given-names>EF</given-names></name><name><surname>Barros</surname><given-names>E</given-names></name><name><surname>Silva</surname><given-names>GB</given-names><suffix>Junior</suffix></name></person-group><source>Nefrologia tropical</source><publisher-loc>S&#x000e3;o Paulo</publisher-loc><publisher-name>Balieiro</publisher-name><year>2019</year></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Khoury</surname><given-names>JM</given-names></name></person-group><article-title>The search for a high-sensitiviy creatinine assay: is symmetric
dimethylarginine ready for prime time in humans?</article-title><source>Clin Lab News</source><year>2018</year><volume>44</volume><fpage>18</fpage><lpage>21</lpage></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>RA</given-names></name><name><surname>Bezerra</surname><given-names>MX</given-names></name><name><surname>Souza</surname><given-names>VL</given-names><suffix>Neto</suffix></name><name><surname>Moror&#x000f3;</surname><given-names>DD</given-names></name><name><surname>Andrade</surname><given-names>IC</given-names></name></person-group><article-title>Children with kidney diseases: association between nursing
diagnoses and their diagnostic indicators</article-title><source>Acta Paul Enferm</source><year>2017</year><volume>30</volume><fpage>73</fpage><lpage>79</lpage></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freitas</surname><given-names>CS</given-names></name><name><surname>Higa</surname><given-names>LM</given-names></name><name><surname>Sacramento</surname><given-names>CQ</given-names></name><name><surname>Ferreira</surname><given-names>AC</given-names></name><name><surname>Reis</surname><given-names>PA</given-names></name><name><surname>Delvecchio</surname><given-names>R</given-names></name><etal>et al</etal></person-group><article-title>Yellow fever virus is susceptible to sofosbuvir both in vitro and
in vivo</article-title><source>PLoS Negl Trop Dis</source><year>2019</year><volume>13</volume><elocation-id>e0007072</elocation-id><pub-id pub-id-type="pmid">30699122</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>AC</given-names></name><name><surname>Reis</surname><given-names>PA</given-names></name><name><surname>Freitas</surname><given-names>CS</given-names></name><name><surname>Sacramento</surname><given-names>CQ</given-names></name><name><surname>Villas B&#x000f4;as Hoelz</surname><given-names>L</given-names></name><name><surname>Bastos</surname><given-names>MM</given-names></name><etal>et al</etal></person-group><article-title>Beyond members of the Flaviviridae family, sofosbuvir also
inhibits chikungunya virus replication</article-title><source>Antimicrob Agents Chemother</source><year>2019</year><volume>63</volume><elocation-id>e01389-18</elocation-id><pub-id pub-id-type="pmid">30455237</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Islan</surname><given-names>GA</given-names></name><name><surname>Dur&#x000e1;n</surname><given-names>M</given-names></name><name><surname>Cacicedo</surname><given-names>ML</given-names></name><name><surname>Nakazato</surname><given-names>G</given-names></name><name><surname>Kobayashi</surname><given-names>RK</given-names></name><name><surname>Martinez</surname><given-names>DS</given-names></name><etal>et al</etal></person-group><article-title>Nanopharmaceuticals as a solution to neglected diseases: is it
possible?</article-title><source>Acta Trop</source><year>2017</year><volume>170</volume><fpage>16</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">28232069</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname><given-names>ZG</given-names></name><name><surname>Romano</surname><given-names>AP</given-names></name><name><surname>Elkhoury</surname><given-names>AN</given-names></name><name><surname>Flannery</surname><given-names>B</given-names></name></person-group><article-title>Evolu&#x000e7;&#x000e3;o hist&#x000f3;rica da vigil&#x000e2;ncia epidemiol&#x000f3;gica e do controle da
febre amarela no Brasil</article-title><source>Rev Pan-Amaz Saude</source><year>2011</year><volume>2</volume><fpage>11</fpage><lpage>26</lpage></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindsey</surname><given-names>NP</given-names></name><name><surname>Horiuchi</surname><given-names>KA</given-names></name><name><surname>Fulton</surname><given-names>C</given-names></name><name><surname>Panella</surname><given-names>AJ</given-names></name><name><surname>Kosoy</surname><given-names>OI</given-names></name><name><surname>Velez</surname><given-names>JO</given-names></name><etal>et al</etal></person-group><article-title>Persistence of yellow fever virus-specific neutralizing
antibodies after vaccination among US travellers</article-title><source>J Travel Med</source><year>2018</year><volume>25</volume><elocation-id>tay108</elocation-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindsey</surname><given-names>NP</given-names></name><name><surname>Schroeder</surname><given-names>BA</given-names></name><name><surname>Miller</surname><given-names>ER</given-names></name><name><surname>Braun</surname><given-names>MM</given-names></name><name><surname>Hinckley</surname><given-names>AF</given-names></name><name><surname>Marano</surname><given-names>N</given-names></name><etal>et al</etal></person-group><article-title>Adverse event reports following yellow fever
vaccination</article-title><source>Vaccine</source><year>2008</year><volume>26</volume><fpage>6077</fpage><lpage>6082</lpage><pub-id pub-id-type="pmid">18809449</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Douam</surname><given-names>F</given-names></name><name><surname>Ploss</surname><given-names>A</given-names></name></person-group><article-title>Yellow fever virus: knowledge gaps impeding the fight against an
old foe</article-title><source>Trends Microbiol</source><year>2018</year><volume>26</volume><fpage>913</fpage><lpage>928</lpage><pub-id pub-id-type="pmid">29933925</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vannice</surname><given-names>K</given-names></name><name><surname>Wilder-Smith</surname><given-names>A</given-names></name><name><surname>Hombach</surname><given-names>J</given-names></name></person-group><article-title>Fractional-dose yellow fever vaccination: advancing the evidence
base</article-title><source>N Engl J Med</source><year>2018</year><volume>379</volume><fpage>603</fpage><lpage>605</lpage><pub-id pub-id-type="pmid">29995585</pub-id></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dixit</surname><given-names>R</given-names></name><name><surname>Herz</surname><given-names>J</given-names></name><name><surname>Dalton</surname><given-names>R</given-names></name><name><surname>Booy</surname><given-names>R</given-names></name></person-group><article-title>Benefits of using heterologous polyclonal antibodies and
potential applications to new and undertreated infectious
pathogens</article-title><source>Vaccine</source><year>2016</year><volume>34</volume><fpage>1152</fpage><lpage>1161</lpage><pub-id pub-id-type="pmid">26802604</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krol</surname><given-names>E</given-names></name><name><surname>Brzuska</surname><given-names>G</given-names></name><name><surname>Szewczyk</surname><given-names>B</given-names></name></person-group><article-title>Production and Biomedical Application of Flavivirus-like
Particles</article-title><source>Trends Biotechnol</source><comment>In Press</comment><year>2019</year></element-citation></ref></ref-list></back></article>